Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial.

ABSTRACT:

Importance

Propranolol for infantile hemangiomas (IH) has been shown to be effective and relatively safe. However, other less lipophilic β-blockers, such as nadolol, may be preferable in individuals who experience propranolol unresponsiveness or adverse events.

Objective

To document the noninferiority and safety of oral nadolol compared with oral propranolol in infants with IH.

Design, setting, and participants

This double-blind noninferiority prospective study with a noninferiority margin of 10% compared propranolol with nadolol in infants aged 1 to 6 months with problematic IH. The study was conducted in 2 academic pediatric dermatology centers in Canada between 2016 and 2020. Infants aged 1 to 6 months with a hemangioma greater than 1.5 cm on the face or 3 cm or gr

SUBMITTER: Pope E 

PROVIDER: S-EPMC8576629 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature